Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One laser, many skin fixes? trial tests 1550nm device on scars and wrinkles

NCT ID NCT06868615

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing a 1550nm non-ablative fractional laser on adults with skin concerns such as acne scars, wrinkles, and dark spots. The trial enrolls about 200 people aged 18 to 70. Participants receive laser treatment, then answer questionnaires about their experience. Dermatologists also review before and after photos to judge improvement and track side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
1550nm non-ablative fractional laser
What this could lead to
If it works, this could offer a single device option for several skin concerns, from acne scars to wrinkles and dark spots.
What could go wrong
This is a general-use study collecting patient feedback, not a controlled comparison. Results may not show clear improvement, and laser treatment can cause redness, swelling, or pigment changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subjects between 18 to 70 years of age. 2. Dermatologic condition that can be addressed by the laser, including but not limited to: 1. Wrinkles 2. Scars 3. Acne Scars 4. Active Acne 5. Dyschromia 6. Cutaneous Lesions such as Age or Sun Spots 7. Melasma 8. Laxity 3. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes. 4. Willingness to comply with the following during the study, including the follow-up period: 1. maintain consistent skin care regimen on treated areas. 2. cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher. 3. refrain from using systemic corticosteroids, according to Investigator discretion. 4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion. 5. refrain from any other procedures in the treatment areas. 5. Willingness and ability to comply with study instructions and return for required visits. 6. Subject has read and signed a written informed consent form. 7. Subject lives within 50 miles of study site. 8. Willingness to shave hair in intended treatment area Exclusion Criteria: 1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g., 2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin) 3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery) 4. Active vitiligo, psoriasis, or eczema in the treatment area 5. Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler) 6. Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel) 7. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion. 8. Active suntan and unable or unlikely to refrain from tanning within the follow-up period. 9. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period. 10. Active localized or systemic infection, or an open wound in area being treated. 11. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma) 12. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid) 13. History of connective tissue disease, such as lupus or scleroderma. 14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area). 15. History of gold therapy. 16. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen. 17. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer. 18. For Female: Pregnancy or lactation, or intent to become pregnant within the study period. 19. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension. 20. History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications. 21. Current enrollment in a clinical study of any other unapproved investigational drug or device 22. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AVAVA, Inc.

    RECRUITING

    Waltham, Massachusetts, 02451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.